Statins May Accelerate Onset of Parkinson’s

Statins, which are widely used to lower cholesterol, may end up accelerating the onset of Parkinson’s disease in some patients.

Researchers at Penn State College of Medicine examined insurance claims data from 50 million people. They found 22,000 people that were diagnosed with Parkinson’s, though only 2,322 were newly diagnosed. They identified patients who were taking statins and determined how long they were taking the medication before Parkinson’s was diagnosed.

Patients that were on statins had a higher risk of developing Parkinson’s, the researchers reported in the journal Movement Disorders. Results also indicated that the association between statin use and Parkinson’s was strongest within the first 2.5 years a patient was on the drug. Researchers say that indicates that statins may facilitate the onset of Parkinson’s.

Prior research had suggested that statins might actually protect against Parkinson’s. One studyfound that people who stopped using statins were more likely to be diagnosed with the disease. But a different explanation for that finding has come to light.

“Use of statins may lead to new Parkinson’s disease-related symptoms, thus causing patients to stop using statins,” lead author Xuemei Huang, MD, said in a statement.

She cautioned that the results should not be interpreted as saying statins cause Parkinson’s. Instead, the findings indicate that statins serve no neuroprotective role. In addition, the data did not include people over the age of 65.

“If your mom has Parkinson’s disease and your grandmother has Parkinson’s disease, and you don’t have a family history of heart attacks or strokes, then you might want to ask your physician more questions to understand the reasons and risks of taking statins,” Huang said.


Jonathan Block

Jonathan Block

Jonathan Block is an associate editor at BioCentury, which provides news and information about the biotechnology and pharmaceutical industries. Prior to joining BioCentury in 2019, Jonathan worked for MedShadow as content editor. He has been an editor and writer for multiple pharmaceutical, health and medical publications, including The Pink Sheet, Modern Healthcare, Health Plan Week and Psychiatry Advisor. He holds a BA from Tufts University and is earning an MPH with a focus on health policy from the CUNY Graduate School of Public Health & Health Policy.


Did you find this article helpful?


Latest News

Breaking News – EpiPen Malfunction

Breaking News – EpiPen Malfunction

Just released from the FDA – Pfizer has informed the FDA that they are aware of several continuing problems that people are having using the EpiPen (epinephrine) and EpiPen Jr (epinephrine) auto-injectors and generic versions. Some of the problems are from user error and some from EpiPen malfunction. Here are…

ACE Inhibitors in the Time of Coronavirus

ACE Inhibitors in the Time of Coronavirus

Are you worried about ACE inhibitors and coronavirus? You may be hearing that one of the entry methods for the coronavirus in humans is by attaching to the ACE-2 enzyme. This has raised alarms among those with heart disease who use ACE inhibitors (with names ending in -pril, such as…

  • Advertisement